BioAlliance Pharma establishes new subsidiary, SpeBio, to sell Loramyc in Europe
The 50:50 joint venture, based in the Netherlands, will distribute Loramyc(R) in European Union countries except France where BioAlliance has set up its own sales team, and in Switzerland and Norway, both outside the EU.
Loramyc(R) is a product indicated for oropharyngeal candidiasis in immunodepressed patients. It obtained Marketing Authorization in France in October 2006. BioAlliance is currently awaiting a decision on the reimbursement price.
Under the terms of the contract between BioAlliance Pharma and Spepharm, BioAlliance will receive up to EUR 29.5 million from Spepharm for Loramyc(R) distribution rights in Europe.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.